. 2020 Sep 10;45(Suppl 1):28–42. doi: 10.1111/jcpt.13224

Table 2.

HbA_1c and body weight change from trials that compared QW GLP‐1 RAs with placebo

Trial name, time until primary endpoint	Treatment arms	Permitted concomitant treatments	ETD HbA_1c, % [95% CI]; P‐value (vs placebo)	ETD body weight, kg [95% CI]; P‐value (vs placebo)
AWARD‐1 ¹⁵ , 26 weeks	Dulaglutide 0.75 mg	Metformin and/or pioglitazone	−0.84 [−1.01; −0.67]; <.001	1.27 [95% CI: NR]; <.001 ^a
	Dulaglutide 1.5 mg		−1.05 [−1.22; −0.88]; <.001	−0.24 [95% CI: NR]; .474 ^a
	Exenatide BID 10 µg
	Placebo
AWARD‐8 ²⁴ , 24 weeks	Dulaglutide 1.5 mg	Glimepiride	−1.3 [−1.6; −1.0]; <.001	−0.68 [−1.53; 0.18]; NS
AWARD‐8 ²⁴ , 24 weeks	Placebo	Glimepiride	−1.3 [−1.6; −1.0]; <.001	−0.68 [−1.53; 0.18]; NS
AWARD‐9 ²⁵ , 28 weeks	Dulaglutide 1.5 mg	Insulin glargine ± metformin	−0.77 [−0.97; −0.56]; <.001	−2.41 [−3.19; −1.64]; <.001
AWARD‐9 ²⁵ , 28 weeks	Placebo	Insulin glargine ± metformin	−0.77 [−0.97; −0.56]; <.001	−2.41 [−3.19; −1.64]; <.001
REWIND ⁷ (median follow‐up 5.4 years)	Dulaglutide 1.5 mg	Antihyperglycaemics except DPP4is or GLP‐1 RAs	−0.61 [−0.65; −0.58]; <.0001 (at 5 months' follow‐up)	−1.46 [−1.67; −1.25]; <.0001 (at 5 months' follow‐up)
REWIND ⁷ (median follow‐up 5.4 years)	Placebo	Antihyperglycaemics except DPP4is or GLP‐1 RAs	−0.61 [−0.65; −0.58]; <.0001 (at 5 months' follow‐up)	−1.46 [−1.67; −1.25]; <.0001 (at 5 months' follow‐up)
DURATION‐NEO‐2 ²⁶ , 28 weeks	Exenatide ER AI 2 mg	Metformin	−0.72 [−1.15; −0.30]; .001	−1.3 [−2.3; −0.2]; .020
DURATION‐NEO‐2 ²⁶ , 28 weeks	Placebo	Metformin	−0.72 [−1.15; −0.30]; .001	−1.3 [−2.3; −0.2]; .020
DURATION‐7 ²⁷ , 28 weeks	Exenatide ER 2 mg	Metformin ± insulin glargine	−0.7 [−0.9; −0.5]; <.001	−1.5 [−2.1; −0.8]; <.001
DURATION‐7 ²⁷ , 28 weeks	Placebo	Metformin ± insulin glargine	−0.7 [−0.9; −0.5]; <.001	−1.5 [−2.1; −0.8]; <.001
EXSCEL ²⁸ (median follow‐up 3.2 years)	Exenatide ER 2 mg	Non‐incretin‐based therapies	−0.53 [−0.57; −0.50]; <0.001	−1.27 [−1.40; −1.13]; <.001
EXSCEL ²⁸ (median follow‐up 3.2 years)	Placebo	Non‐incretin‐based therapies	−0.53 [−0.57; −0.50]; <0.001	−1.27 [−1.40; −1.13]; <.001
SUSTAIN 1 ⁸ , 30 weeks	Semaglutide s.c. 0.5 mg	Metformin, OADs (excluding GLP‐1 RAs or DDP4is)	−1.43 [−1.71; −1.51]; <.0001	−2.75 [−3.92; −1.58]; <.0001
	Semaglutide s.c. 1 mg		−1.53 [−1.81; −1.25]; <.0001	−3.56 [−4.74; −2.38]; <.0001
	Placebo
SUSTAIN 5 ²⁹ , 30 weeks	Semaglutide s.c. 0.5 mg	Basal insulin ± metformin	−1.35 [−1.61; −1.50]; <.0001	−2.31 [−3.33; −1.29]; <.0001
	Semaglutide s.c. 1 mg		−1.75 [−2.01; −1.50]; <.0001	−5.06 [ −6.08; −4.04]; <.0001
	Placebo
SUSTAIN 6 ⁶ (median follow‐up 2.1 years)	Semaglutide s.c. 0.5 mg	Non‐incretin‐based therapies	−0.66 [−0.80; −0.52]; .0001	−2.87 [−3.47; −2.28]; <.0001
	Semaglutide s.c. 1 mg		−1.05 [−1.19; −0.91]; <.0001	−4.35 [−4.94; −3.75]; <.0001
	Placebo

Abbreviations: BID, twice‐daily; CI, confidence interval; ETD, estimated treatment difference; exenatide ER, exenatide extended‐release; exenatide ER AI, exenatide ER auto‐injectable; GLP‐1 RA, glucagon‐like peptide‐1 receptor agonist; HbA_1c, glycated haemoglobin; NR, not recorded; NS, non‐significant; QW, once‐weekly; s.c., subcutaneous.

^{^a}

ETD compared with exenatide BID treatment arm.